Glass in Vials Leads to Recall of Several Hospira Products

Hospira is recalling several products because glass particulates were found during product inspection. The presence of glass can lead to serious adverse events, including inflammation of a vein, granuloma, and blockage of blood vessels or life-threatening blood clots.

This recall impacts:

• Bleomycin for Injection, single dose with ONCO-TAIN glass fliptop vial, lot number BL12206A and NDC 61703-332-18. It has an expiration date of June 30, 2024. Bleomycin is used to treat several types of cancer, including head and neck, uterine, cervical, testicular, and lymphoma.
• 4.2% Sodium Biocarbonate Injection, with ABBOJECT glass syringe, lot number GX1542, with NDC for the carton 0409-5534-24 and NDC for the case 0409-5534-14. It has an expiration date of Jan. 1, 2025. It is indicated to treat patients with metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, severe dehydration, , cardiac arrest and severe primary lactic acidosis.
• 8.4% Sodium Biocarbonate Injection, with Lifeshield ABBOJECT glass syringe, lot number HA7295 with NDC for the carton 0409-6637-24 and NDC for the case 0409-6637-14. It has an expiration of March 1, 2025.
• Atropine Sulfate Injection, with Lifeshield ABBOJECT glass syringe, lot number of GY2496 with NDC for the carton 0409-4911-11 and NDC for the case 0409-4911-34. It has an expiration of Feb. 1, 2025. It blocks severe or life-threatening muscarinic effects.

To date, Hospira has not received reports of any adverse events associated with these products.